

Jacob T Painter, PharmD, MBA, PhD

Associate Director for Operations and Core Investigator
Center for Mental Healthcare and Outcomes Research
Department of Veterans Affairs
2200 Fort Roots Drive, Building 58, Room 250
North Little Rock, Arkansas 72114-1706
Phone: (501) 257-1740
Fax: (501) 257-1707
Email: Jacob.Painter@va.gov

Director and Associate Professor
Division of Pharmaceutical Evaluation and Policy
University of Arkansas for Medical Sciences
4301 West Markham Street, Box 522-4
Little Rock, Arkansas 72205-7199
Phone: (501) 686-7123
Fax: (501) 686-5156
Email: JTPainter@uams.edu

EDUCATIONAL EXPERIENCE

Doctor of Philosophy in Pharmaceutical Sciences

University of Kentucky, Graduate School
Dissertation: Chronic opioid use in fibromyalgia syndrome: characteristics and outcomes
Dissertation defended: April 2012
Graduation: May 2012

Graduate Certificate in Informatics

University of Kentucky, Graduate School
Completed 2012

Schutte Fellowship in Pharmaceutical Outcomes and Policy

University of Kentucky, College of Pharmacy
Completed 2011

Master of Business Administration

University of Kentucky, Gatton College of Business and Economics
Summa cum Laude, 2009

Doctor of Pharmacy

University of Kentucky, College of Pharmacy
Magna cum Laude, 2009

PROFESSIONAL EXPERIENCE

Director of the Division of Pharmaceutical Evaluation and Policy

Department of Pharmacy Practice
University of Arkansas for Medical Sciences; Little Rock, Arkansas
November 2020-Present

Associate Director for Operations

Center for Mental Healthcare and Outcomes Research
Central Arkansas Veterans Healthcare System; North Little Rock, Arkansas
April 2019-Present

Associate Professor of Pharmaceutical Evaluation and Policy with Tenure

Department of Pharmacy Practice
University of Arkansas for Medical Sciences; Little Rock, Arkansas
July 2018-Present

Research Health Scientist and Core Investigator

Center for Mental Healthcare and Outcomes Research
Central Arkansas Veterans Healthcare System; North Little Rock, Arkansas
August 2012-Present

Assistant Professor of Pharmaceutical Evaluation and Policy

Department of Pharmacy Practice
University of Arkansas for Medical Sciences; Little Rock, Arkansas
August 2012-Present

Research Assistant for Health Services Research

University of Kentucky; Lexington, Kentucky
July 2011-June 2012

PROFESSIONAL EXPERIENCE (CONTINUED)

Staff Pharmacist

Sears Holdings Corporation; Winchester, Kentucky
June 2009-July 2012

Health Services Research Assistant

Research and Data Management Center; Lexington, Kentucky
March 2009-July 2010

Regulatory Affairs Intern

Procter and Gamble Pharmaceuticals; Mason, Ohio
May 2007-August 2007

TEACHING EXPERIENCE

Course Coordinator

Pharmacy Management (PHPR 7301), Professional Program

Three credit hours, offered annually in the spring, 2012-present (approximately 110 students)
College of Pharmacy, University of Arkansas for Medical Sciences

Pharmacoepidemiology (PSGP 6113), Graduate Program

Three credit hours, offered biannually in the fall, 2013-present (approximately 5 students)
College of Pharmacy, University of Arkansas for Medical Sciences

Pharmaceutical Evaluation & Policy Seminar (PSGP 5109), Graduate Program

One credit hour, offered fall 2014, spring 2017 (approximately 10 students)
College of Pharmacy, University of Arkansas for Medical Sciences

Research in Clinical Care (PHPR 7150), Professional Program

Two credit hours, offered annually in the spring, 2017-present (approximately 5 students)
College of Pharmacy, University of Arkansas for Medical Sciences

Instructor

PHPR 7150 Research in Clinical Care (2017-present)

Professional Program. College of Pharmacy, University of Arkansas for Medical Sciences.

Lectures: Writing a Research Question, Research Methods

PSGP 5113 Research Methods in Pharmaceutical Evaluation and Policy (2015-present)

Graduate Program. College of Pharmacy, University of Arkansas for Medical Sciences.

Lectures: Retrospective Data Sources, Sampling Methods

PSGP 6113 Pharmacoepidemiology (2013-present)

Graduate Program. College of Pharmacy, University of Arkansas for Medical Sciences.

Class sessions: What is Pharmacoepidemiology, Pharmacoepidemiology Study Design, Sample Size Considerations, When to Perform Pharmacoepidemiology Studies, Spontaneous Reporting, Ongoing Systems for Pharmacoepidemiology Studies, Overview of Automated Databases, How to Perform Pharmacoepidemiology Studies, Advanced Approaches to Controlling Confounding, Risk Management, Risk Evaluation and Communication, Validity of Pharmacoepidemiology Drug and Diagnosis Data, Comparative Effectiveness Research, Sequential Statistical Methods, Pharmacoepidemiology and Pharmaceutical Reimbursement, Introduction to Pharmacoeconomics, Quality of Life Measurements, The Future of Pharmacoepidemiology.

PHPR 7301 Pharmacy Management (2012-present)

Professional Program. College of Pharmacy, University of Arkansas for Medical Sciences

Lectures: Introduction to Pharmacy Management, Business Planning, Marketing I & II, Recruiting & Interviewing, Managing the Workplace, Risk Management, Pharmacy Informatics, Community Inventory

Team-Based Learning Sessions: Communication, Risk Management

Case Conferences: Management, Marketing, Human Resources, Financials, Cost of Dispensing, CV/Resume

PPS 940 Evidence Base for Pharmacy Practice (2010-2012)

Professional Program. College of Pharmacy, University of Kentucky

Introduction to Pharmacoeconomics, Introductory Biostatistics I and II, Introduction to Study Design, Measurement in Research, Levels of Measurement.

Graduate student committee chair

Laura Gressler Pharmaceutical Evaluation and Policy Master's Program.

Graduation Date: July 2017

Thesis: *The relationship between concomitant opioid-benzodiazepine use and adverse outcomes among US Veterans*

Initial placement: Doctoral student at University of Maryland, Pharmaceutical Health Services Research

Niranjan Kathe. Pharmaceutical Evaluation and Policy Doctoral Program.

Graduation date: August 2019

Dissertation: Assessing the spillover effects of Medicaid expansion compared to non-expansion on existing Medicaid enrollees, children of Medicaid eligible parents, and on the commercially insured population

Initial placement: Senior Manager at Complete HEOR Solutions

Mrinmayee Lakkad. Pharmaceutical Evaluation and Policy Doctoral Program.

Anticipated graduation date: May 2020

Dissertation: To be determined

Current status: Second year of didactic curriculum.

Graduate student committee member

Joshua Brown. Pharmaceutical Evaluation and Policy Master's Program

Graduation date: May 2014

Dissertation: *Comparison of Inappropriate Prescribing Criteria for the Elderly – Beers 2003, Beers 2012 and STOPP Criteria – In a Large Administrative Claims Database*

Initial placement: Research Assistant and Pfizer/Humana Pharmacy Fellow pursuing PhD in Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, Kentucky

Anand Shewale. Pharmaceutical Evaluation and Policy Doctoral Program

Graduation date: May 2016

Dissertation: *Comparative effectiveness of Hyaluronic acid injections for delay of surgical interventions among patients with knee osteoarthritis*

Initial placement: Manager, Health Economics Outcomes Research, Allergan, Irvine, CA

Anuj Shah. Pharmaceutical Evaluation and Policy Doctoral Program

Anticipated graduation date: December 2017

Dissertation: *Impact of Medicaid expansion under ACA on inpatient and emergency room utilization and substance use disorder treatment*

Initial placement: Data Scientist at Genentech, Washington, DC

Mir Ali. Health Systems and Services Research Doctoral Program

Graduation date: December 2018

Dissertation: *Geographic variation in prescription drug spending*

Current status: Research Fellow, University of Arkansas for Medical Sciences.

Pharmacy resident research mentorship

Amanda Bellile. PGY2 Pain and Palliative Care

Project: *The effect of substance use disorder diagnosis on post-surgical opioid length of therapy*

Megan Adams. PGY1 Pharmacy Resident

Project: *Impact of CDC Guidelines on opioid prescribing in a VAMC emergency department*

Lisa Dragic. PGY2 Pain and Palliative Care

Project: *Effect of pharmacy intervention for opioid tapering*

Emily Ellsworth. PGY1 Pharmacy Resident

Project: *Effect of gabapentin on post-operative opioid consumption in the geriatric population*

Thomas Webb. PGY2 Pain and Palliative Care

Project: *Comparing effectiveness of gabapentin and pregabalin in the treatment of neuropathic pain: a retrospective cohort of palliative care outpatients*

Amy Brotherton. PGY1 Pharmacy Resident

Project: *System-Wide Implementation of Extended-Infusion Piperacillin/Tazobactam at a Teaching Hospital*

Sarah Lewis. PGY1 Community Pharmacy Resident

Project: *The Effect of Appointment-Based Medication Synchronization on Clinical Services in a Community Pharmacy*

Teaching development activities

Teaching Scholars

University of Arkansas for Medical Science; Graduate, June 2014

Teaching Essentials Institute

American Association of Colleges of Pharmacy; Team Member, May 2013

48th Graduate Summer Session in Epidemiology

University of Michigan; Attendee, July 2013

PUBLICATIONS

Refereed original research – first, senior, or corresponding author

1. Dragic L, Webb T, Chandler M, Harrington SB, McDade E, Dayer L, **Painter JT**. Comparing Effectiveness of Gabapentin and Pregabalin in Treatment of Neuropathic Pain: A Retrospective Cohort of Palliative Care Outpatients. *Journal of Pain and Palliative Care Pharmacotherapy*. 2020 Dec; 34(4):192-196. doi: 10.1080/15360288.2020.1784354.
2. Pritchard ER, Dayer L, Belz J, Forseth B, Harrington S, **Painter JT**. (2020). Effect of cannabis on opioid use in patients with cancer receiving palliative care. *Journal of the American Pharmacists Association*, 60(1), 244-247.
3. Dayer LE, Kling B, Petersen M, Lakkad M, **Painter JT**. Association of the "CDC Guideline for Prescribing Opioids for Chronic Pain" with Emergency Department Opioid Prescribing. *Journal of Emergency Medicine*. 2019; 57(5): 597-602.
4. Stolarz AJ, Lakkad M, Klimberg S, **Painter JT**. Calcium channel blockers and risk of lymphedema among breast cancer patients: nested case control study. *Cancer Epidemiology, Biomarkers & Prevention*. 2019; 28(11): 1809-1815.
5. Chopra D, Shah A, Vadhariya A, **Painter JT**. The risk of varenicline-induced seizure among those who have attempted to quit smoking using pharmacotherapy. *Drug Safety*. 2019; 97: 169-173.
6. **Painter JT**, Gressler L, Kathe N, Slabaugh SL, Blumenschein K. Consumer willingness to pay for pharmacy services: An updated review of the literature. *Research in Social and Administrative Pharmacy*. 2018; 14(12) 1091-1105. doi: 10.1016/j.sapharm.2018.01.010.
7. Kathe NK, Shah A, Said Q, **Painter JT**. DPP-4 Inhibitor-induced rheumatoid arthritis among diabetics: a nested case-control study. *Diabetes Therapy*. 2018; 9(1): 141-151. doi: 10.1007/s13300-017-0353-5.
8. Gressler LE, Hudson TJ, Martin BC, **Painter JT**. Relationship between Concomitant Opioid-Benzodiazepine Use and Adverse Outcomes Among US Veterans. *PAIN*. 2017; 159(3): 451-459. doi: 10.1097/j.pain.00000001111.
9. **Painter JT**, Martin BC, Li C, Bodhani A, Pyne JM. Genetic Testing for CYP-2D6 Polymorphism Prior to Selective Serotonin Reuptake Inhibitor Prescribing: Results from a Decision Analysis Model. *Journal of Psychiatry and Cognitive Behavior*. 2017; 4(123): 1-7. doi: 10.29011/2574-7762.000023.
10. **Painter JT**, Pyne JM, Austen MA, Fortney JC. Cost-effectiveness of Telemedicine-Based Collaborative Care for Posttraumatic Stress Disorder. *Psychiatric Services*. 2017; 68: 1-7. doi: 10.1176/appi.ps.201600485.
11. **Painter JT**, Owen R, Henderson KL, Bauer MS, Mittal D, Hudson TJ. Analysis of the Appropriateness of Off-Label Antipsychotic Use for Mental Health Indications in a Veteran Population. *Pharmacotherapy*. 2017; 37(4): 438-446. doi: 10.1002/phar.1910.
12. Hayes CJ, **Painter JT**. A Comprehensive Review of Opioid-Induced Allodynia: Discussion of the Current Evidence and Clinical Implications. *Journal of Opioid Management*. 2017; 13(2): 95-103. doi: 10.5055/jom.2017.0373.
13. **Painter JT**, Fortney JC, Gifford AL, Rimland D, Monson T, Rodriguez-Barradas MC, Pyne JM. Cost-effectiveness of collaborative care for depression in human immunodeficiency virus clinics. *Journal of Acquired Immune Deficiency Syndromes*. 2015; 70 (4): 377-385. doi: 10.1097/QAI.0000000000000732.
14. **Painter JT**, Crofford LJ, Talbert J, Butler JS. Healthcare costs associated with chronic opioid use and fibromyalgia syndrome: a propensity-matched case control. *American Journal of Pharmacy Benefits*. 2014; 6(6): e177-e184.

15. **Painter JT**, Talbert J, Crofford LJ. Geographic variation of chronic opioid use for fibromyalgia. *Clinical Therapeutics*. 2013; 35(3):303-311. doi: 10.1016/j.clinthera.2013.02.003.
16. **Painter JT**, Crofford, LJ. Chronic opioid use in fibromyalgia: a clinical review. *Journal of Clinical Rheumatology*. 2013; 19(2):72-77. doi: 10.1097/RHU.0b013e3182863447.
17. **Painter JT**, Fink III JL. Educational innovations: Categories of bulletin board postings designed to increase awareness of contemporary pharmaceutical policy issues. *Pharmacy Practice*. 2010; 8(4):255-259. doi: 10.4321/s1886-36552010000400009.

Refereed original research – contributing author

1. Landes SJ, Jegley SM, Kirchner JE, Areno JP, Pitcock JA, Abrahan TH, McBain SA, Singh RS, Bollinger MJ, **Painter JT**, Jones DE, Matarazzo BB, Reer MA, Comtois KA. Adapting Caring Contacts for Veterans in a Department of Veterans Affairs Emergency Department: Results From a Type 2 Hybrid Effectiveness-Implementation Pilot Study. *Frontiers in Psychiatry*. In press: October 13, 2021.
2. Callaway K, Lakkad M, **Painter JT**, Dayer L, Oswalt AK. The Impact of Continuous Infusion Compared to Intravenous Bolus Administration of Pantoprazole on Length of Intensive Care Unit Stay in Critically Ill Patients. *Journal of Pharmacy Practice*. Electronically published: August 10, 2021. doi:10.1177/08971900211036096.
3. Muzzio K, Chandler M, **Painter JT**, Dragic L. Characterizing Patients after Opioid Taper in a VA Medical Center. *Journal of Pain and Palliative Care Pharmacotherapy*. In press: June 2021. doi:10.1080/15360288.2021.1900492.
4. Chopra D, Li C, **Painter JT**, Bona JP, Nookaew I, Martin BC. Characteristics and Network Influence of Providers Involved in the Treatment of Patients with Chronic Back, Neck or Joint Pain in Arkansas. *Journal of Pain*. In press: June 24, 2021. S1526-5900(21)00246-7. doi: 10.1016/j.jpain.2021.06.002.
5. Klucher JM, Davis K, Lakkad M, **Painter JT**, Dare RK. Risk factors and clinical outcomes associated with blood culture contamination. *Infectious Control and Hospital Epidemiology*. Electronically published: April 26, 2021. doi:10.1017/ice.2021.111.
6. Dare RK, Lusardi K, Pearson C, McCain KD, Daniels, B Van S, Rico RC, **Painter JT**, Lakkad M, Rosenbaum ER, Bariola JR. Clinical Impact of Accelerate Pheno™ Rapid Blood Culture Detection System in Bacteremic Patients. *Clinical Infectious Diseases*. In press: May 2020. doi:10.1093/cid/ciaa649.
7. Matthieu MM, Ounpraseuth ST, **Painter JT**, Waliski A, Williams JS, Hu B, Smith R, Garner KK. Evaluation of the national implementation of the VA Diffusion of Excellence Initiative on Advance Care Planning via Group Visits: Protocol for a quality improvement evaluation. *Implementation Science Communications*. 2020; 1(1): 1-10. doi:10.21203/rs.2.21754/v1.
8. Hammond DA, Flowers HJ, Meena N, **Painter JT**, Rech MA. Cost avoidance associated with clinical pharmacist presence in a medical intensive care unit. *Journal of the American College of Clinical Pharmacy*. 2019. doi:10.1002/jac5.1111.
9. Dayer LE, **Painter JT**, McCain K, King J, Cullen J, Foster HR. A Recent History of Opioid Use in the US: Three Decades of Change. *Substance Use and Misuse*. 2019; 54(2): 331-339. doi: 10.1080/10826084.2018.1517175
10. Midboe AM, Martino S, Krein SL, Frank JW, **Painter JT**, Chandler M, Schroeder A, Fenton BT, Troszak L, Erhardt T, Kerns RD, Becker WC. Testing Implementation Facilitation of a Primary Care-Based Collaborative Care Clinical Program Using a Hybrid Type III Interrupted Time Series Design: A Study Protocol. *Implementation Science*. 2018; 13(1): 145-156. doi: 10.1186/s13012-018-0838-2.
11. Hammond DA, Rowe JM, Wiley TL, **Painter JT**. Evaluation of an elective course for preparing students to pursue postgraduate residency training. *Currents in Pharmacy Teaching and Learning*. In press: June 2018. doi: 10.1016/j.cptl.2018.06.007.
12. Hammond DA, Clem O, **Painter JT**, McCain K, Cullen J, Brotherton A, Chopra D, Meena NK. Prospective, open-label trial of early concomitant vasopressin and norepinephrine versus initial norepinephrine monotherapy in septic shock. *Pharmacotherapy*. 2018; 38(5): 531-538. doi: 10.1002/phar.2105
13. Becker WC, Mattocks KM, Frank JM, Bair MJ, Jankowski RL, Kerns RD, **Painter JT**, Fenton BT, Midboe AM, Martino S. Mixed methods formative evaluation of a collaborative care program to decrease risky opioid prescribing and increase non-pharmacologic approaches to pain management. *Addictive Behaviors*. In Press (2018) doi: 10.1016/j.addbeh.2018.03.009

14. Hammond DA, **Painter JT**, Meena NK. Incidence of clinically significant hypotension stratified by vasopressin duration. *Journal of Intensive Care Medicine*. 2019; 34(1): 77-78.
15. Hammond DA, James TB, Atkinson LN, **Painter JT**, Lusardi K. Changing the Time of Blood Collection to Determine Vancomycin Concentrations in Intensive Care Unit Patients. *Critical Care Nurse*. 2018; 38(1): 24-28. doi: 10.4037/ccn2018XXX.
16. Hammond DA, **Painter JT**, Chiu T, Meena NK. Non-Pharmacist Healthcare Providers' Knowledge of and Opinions Regarding Medication Costs in Critically Ill Patients. *Hospital Pharmacy*. 2018; 53(3) 188-193.
17. Hammond DA, Cullen J, **Painter JT**, McCain K, Brotherton AL, Meena NK. Efficacy and Safety of the Early Addition of Vasopressin to Norepinephrine in Septic Shock. *Journal of Intensive Care Medicine*. ePub: August 2017. doi: 10.1177/0885066617725255.
18. Hudson TJ, **Painter JT**, Gressler LE, Lu L, Williams JS, Booth BM, Martin BC, Sullivan MD, Edlund MJ. Factors Associated with Opioid Initiation in OEF/OIF/OND Veterans with Traumatic Brain Injury. *Pain Medicine*. ePub: July 2017. doi: 10.1093/pm/pnx208.
19. Hammond DA, McCain K, **Painter JT**, Clem OA, Cullen J, Brotherton AL, Chopra D, Meena NK. Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock. *Journal of Intensive Care Medicine*. ePub: June 2017. doi: 10.1177/0885066617714209.
20. Hammond DA, Killingsworth CA, **Painter JT**, Pennick RE, Chatterjee K, Boye B, Meena N. Impact of targeted educational interventions on appropriateness of stress ulcer prophylaxis in critically ill adults. *Pharmacy Practice*. 15(3): 948-953. doi: 10.18549/PharmPract.2017.03.948.
21. Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, **Painter JT**, Martin BC. Comparative effectiveness of intra-articular hyaluronic acid and corticosteroid injections on the time to surgical knee procedures. *The Journal of Arthroplasty*. ePub: July 2017. doi: 10.1016/j.arth.2017.07.007.
22. Hammond DA, Atkinson LN, James TB, **Painter JT**, Lusardi K. Effects of staff education and standardizing dosing and collection times for vancomycin troughs to morning blood collections on trough appropriateness in ward patients. *Pharmacy Practice*. 2017; 15(2): 949-953. doi: 10.18549/PharmPract.2017.02.949.
23. Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth S, **Painter JT**, Martin BC. Comparative effectiveness of low, moderate and high molecular weight hyaluronic acid injections in delaying time to knee surgery. *Arthroplasty*. 2017; 32: 2952-2957. doi: 10.1016/j.arth.2017.04.041.
24. Hudson TJ, **Painter JT**, Martin BC, Austen MA, Williams JS, Fortney JC, Sullivan MD, Edlund MJ. Pharmacoepidemiologic Analyses of Opioid Use among OEF/OIF/OND Veterans. *PAIN*. 2017; 158(6): 1039-1045. doi: 10.1097/j.pain.0000000000000874.
25. Hammond D, **Painter JT**, Oyler D, Branan T, Devlin J, Barletta J, Bolesta S, Dunn B, Haney J, Juang P, Kane-Gill S. Perceived motivating factors and barriers for the completion of postgraduate training among American pharmacy students prior to beginning advanced pharmacy practice experiences. *American Journal of Pharmacy Education*. 2017; 81(8): 90-97. doi: 10.5688/ajpe81590.
26. Drummond KL, **Painter JT**, Curran GM, Stanley R, Gifford AL, Rodriguez-Barradas M, Rimland D, Monson TP, Pyne JM. HIV patient and provider feedback on a telehealth collaborative care for depression intervention. *AIDS Care*. 2017; 29(3): 290-298. doi: 10.1080/09540121.2016.1255704.
27. Hammond DA, **Painter JT**, Bhandari N. Effect of etomidate on pneumonia development in critically ill, non-trauma patients. *Journal of Intensive Care Medicine*. ePub: December 2016. doi: 10.1177/0885066616686052.
28. Hammond DA, Hughes CA, **Painter JT**, Pennick RE, Chatterjee K, Boye B, Meena N. Impact of Targeted Educational Interventions on Clostridium Difficile Infection Treatment in Critically Ill Adults. *Hospital Pharmacy*. 2016; 51(11): 901-906. doi: 10.1310/hpj5111-901.
29. Hammond DA, Smith MN, **Painter JT**, Meena NK, Lusardi K. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study. *Pharmacotherapy*. 2016; 36(5): 463-471. doi: 10.1002/phar.1738.
30. Brown JD, Hutchinson LC, Li C, **Painter JT**, Martin BC. Predictive validity of the Beers and STOPP criteria to detect adverse drug events, hospitalizations, and emergency department visits in the United States. *Journal of the American Geriatrics Society*. 2016; 64(1) 22-30. doi: 10.1111/jgs.13884.

31. Cobaugh DJ, Gainor C, Gaston CL, Kwong TC, Magnani B, McPherson ML, **Painter JT**, Krenzelok EP. The opioid abuse and misuse epidemic: Implications for pharmacists in hospitals and health systems. *American Journal of Health-System Pharmacy*. 2014; 71(18):1539-1554. doi: 10.2146/ajhp140157.

Other professional publications

1. **Painter JT**, Curran G. (2020) Implementation and Evaluation of Pharmacy Services. In *Remington: The Science and Practice of Pharmacy 23e*. London: Pharmaceutical Press.
2. Teeter B, **Painter JT**. (2019) Marketing Applications. In *Pharmacy Management: Essentials for All Practice Settings 5e* (pp XX). New York: McGraw-Hill.
3. Garner K, George M, **Painter JT**. Palliative Pain Management during an Opioid Epidemic. *Arkansas Hospitals*. ePub; Spring 2019: 40-41. Available: <http://www.arkhospitals.org/archive/arkhospmagpdf/AHASpring2019.pdf>
4. **Painter JT**, Moore G, Morris B. Addressing medication non-adherence through implementation of an appointment-based model synchronization network. *America's Pharmacist*. ePub: October 2015. doi: 10.13140/RG.2.1.1598.5360
5. Lewis S, **Painter JT**, Price H, Stafford R. The Effect of Appointment-Based Medication Synchronization on Clinical Services in a Community Pharmacy. *Computer Talk for the Pharmacist*. 2015; 35(3): 15-18.
6. **Painter JT**, Cobaugh DJ. Preventing Opioid Abuse: Prescription drug monitoring programs can play important role. *Clinical and Forensic Toxicology News*. March 2015.

Conference presentations

1. Matthieu MM, Ounpraseuth, **Painter JT**, Waliski A., Williams JS., Hu B., Smith R., & Garner KK (December 2020). Advance Care Planning via Group Visits: The impact of funding staff positions for implementing a diffusion of excellence program (Poster session).
2. Lakkad M, **Painter JT**. Opioid Prescribing for Chronic Pain and Impact of CDC Guidelines in an Academic Center Emergency Department: Interrupted Time Series Analysis. Poster B-189. Academy Health Annual Research Meeting. June 3, 2019.
3. Hung D, Kathe N, **Painter JT**. Pregabalin use on Diabetic Neuropathy Patients and the Risk of Heart Failure. Poster XX. International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, Maryland. May 21, 2018.
4. Crader M, **Painter JT**. Impact of Vancomycin Loading Doses on MRSA Vancomycin MICs. Poster XXX. American Society of Health-System Pharmacists Midyear Clinical Meeting. Anaheim, California. December 2, 2018.
5. Kling B, Breckling M, Lakkad M, Pritchard R, **Painter JT**, Dayer LE. The impact of CDC guidelines on opioid prescribing in an academic medical center emergency department. Poster XXX. American Society of Health-System Pharmacists Midyear Clinical Meeting. Anaheim, California. December 2, 2018.
6. Dare R, McCain K, Lusardi K, Lakkad M, **Painter JT**, Bariola JR. Impact of Accelerate Pheno™ Rapid Blood Culture Detection System on Laboratory and Clinical Outcomes in Bacteremic Patients. Podium 1758. Infectious Disease Week 2018. San Francisco, California. October 6, 2018.
7. **Painter JT**, Hayes C, Martin B, Hudson T. The Role of Race/Ethnicity in Opioid Prescribing Among Veterans with Chronic Non-Cancer Pain. Poster B-75. Academy Health Annual Research Meeting. Seattle, Washington. June 25, 2018.
8. Gressler L, Hudson T, **Painter JT**. The Effect of Psychotropic Load on Adverse Outcomes among Veterans Using Opioids. Academy Health Annual Research Meeting. Seattle, Washington. June 25, 2018.
9. Acharya M, **Painter JT**. New Oral Anticoagulants and the Risk of Vasculitis: A Nested Case-Control Study. Poster PCV1. International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, Maryland. May 19, 2018.
10. Kathe N, **Painter JT**. Comparative Effectiveness of Second-Line Anti-Diabetic Agents in Delaying Treatment Intensification. Poster PDB28. International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, Maryland. May 19, 2018.

11. Hung DT, Kathe N, **Painter JT**. Pregabalin Use for Diabetic Neuropathy Patients and the Risk of Heart Failure. Poster PSY2. International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, Maryland. May 19, 2018.
12. Shewale AR, Barnes LC, Fischbach LA, Ounpraseuth S, **Painter JT**, Martin BC. Conflicting Comparative Effectiveness Evidence of Hyaluronic Acid Using Real World Data Evidence. An Update Using a High Dimensional Propensity Score Matching Approach. Poster: PMS11. International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, Massachusetts. May 21, 2017.
13. Hammond DA, Flowers H, **Painter JT**. Cost Avoidance from Pharmacist Interventions Documented in a Medical ICU. Poster: 37. 46th Critical Care Congress. Honolulu, Hawaii: January 21, 2017. Poster: 37. American College of Clinical Pharmacy Annual Meeting. Hollywood, Florida: October 23, 2016.
14. Hammond DA, Cullen J, McCain K, **Painter JT**. Retrospective, Cohort Study of Norepinephrine and Vasopressin versus Norepinephrine Alone for Septic Shock: Poster: 1451. 46th Critical Care Congress. Honolulu, Hawaii: January 21, 2017.
15. Clem OA, **Painter JT**, Cullen J, Hammond DA. Randomized Controlled Trial of Norepinephrine and Vasopressin versus Norepinephrine Alone for Septic Shock. Poster: 1350. 46th Critical Care Congress. Honolulu, Hawaii: January 21, 2017. Poster: 1350. American Colleges of Clinical Pharmacy Annual Meeting. Hollywood, Florida. October 25, 2016.
16. Hammond DA, Clem OA, Brotherton AL, **Painter JT**. Discontinuation of Vasopressin before Norepinephrine in Recovery Phase of Septic Shock: Cohort Study. Poster: 1432. 46th Critical Care Congress. Honolulu, Hawaii: January 21, 2017.
17. Hammond DA, Vines C, McPhee A, Bhandari NR, Jones K, Meena N, **Painter JT**. Effect of etomidate on pneumonia development in critically ill, non-trauma patients. Poster: 41299. 46th Critical Care Congress. Honolulu, Hawaii: January 21, 2017.
18. **Painter JT**, Hudson TJ. Determining the Appropriateness of Off-Label Antipsychotic Use for Mental Health Indications. Podium: 12510. 2016 Academy Health Behavioral Health Interest Group. Boston, Massachusetts: June 25, 2016.
19. **Painter JT**, Fortney JC, Gressler L, Pyne JM. Comparing the Sensitivity of Generic and Disease-Specific Effectiveness Measures in Persons with PTSD. Poster: 12509. 2016 Academy Health Behavioral Health Interest Group. Boston, Massachusetts: June 25, 2016. Poster: 1063. 2016 Academy Health Annual Research Meeting. Boston, Massachusetts: June 27, 2016.
20. **Painter JT**, Fortney JC, Pyne JM. Cost-Effectiveness of Telemedicine-Based Collaborative Care for PTSD. Poster: 1062. 2016 Academy Health Annual Research Meeting. Boston, Massachusetts: June 27, 2016.
21. Chopra D, Shah A, **Painter JT**. The risk of seizures with Varenicline use among patients who have attempted to quit smoking using pharmacotherapy or nicotine replacement therapy. Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 23, 2016. *Value in Health*, 19 (3): A265.
22. Kathe N, Shah A, **Painter JT**. Impact of dipeptidyl peptidase-4 inhibitors on the risk of rheumatoid arthritis. Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 24, 2016. *Value in Health*, 19 (3): A225.
23. Bhandari NR, Shewale AR, Kathe NJ, Shah AB, **Painter JT**. Association Between the Use of Doxorubicin and Risk of Developing Hepatotoxicity Among Cancer Patients. Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 24, 2016. *Value in Health*, 19 (3): A134.
24. Shewale AR, Bhandari NR, Kathe N, Hammond DA, **Painter JT**. Off-label and on-label use of testosterone among the commercially insured population in the United States. Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 24, 2016. *Value in Health*, 19 (3): A261.
25. Shewale AR, Bhandari NR, Kathe N, Hammond DA, **Painter JT**. Geographic variation in off-label and on-label use of testosterone among the commercially insured population in the United States. Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 24, 2016. *Value in Health*, 19 (3): A262.

26. Shewale AR, Bhandari NR, Kathe N, Hammond DA, **Painter JT**. Male and female users of testosterone among the commercially insured population in the United States. Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 24, 2016. *Value in Health*, 19 (3): A264.
27. Shewale AR, Barnes LC, Fischbach LA, Ounpraseuth S, **Painter JT**, Martin BC. Characterization of initial treatment strategies used to manage incident knee osteoarthritis." Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 24, 2016. *Value in Health*, 19 (3): A238.
28. Gressler, L.E., Kathe N, **Painter, JT**. Assessing the Potential Risk of Serotonin Syndrome in Tapentadol Users. Poster: 21st Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington, DC, USA. May 25, 2016. *Value in Health*, 19 (3): A241.
29. Wiley T, Rowe J, **Painter JT**, Hammond DA. Student confidence, intentions, and factors regarding pursuit of postgraduate residency training following an elective. Poster: 2016 American Association of Colleges of Pharmacy Annual Meeting. Anaheim, California: July 23, 2016.
30. Wiley T, Rowe J, **Painter JT**, Castleberry AN, Hammond DA. Qualitative analysis of students' opinions regarding a fast-paced, interactive learning session on pulmonary arterial hypertension. Poster: 2016 American Association of Colleges of Pharmacy Annual Meeting. Anaheim, California: July 23, 2016.
31. Castleberry AN, Wiley T, **Painter JT**, Hammond DA. Students' in-class knowledge of pulmonary arterial hypertension stratified by cognitive domain level and exam performance. Poster: 2016 American Association of Colleges of Pharmacy Annual Meeting. Anaheim, California: July 23, 2016.
32. Hammond DA, Wiley T, Castleberry AN, **Painter JT**. Pulmonary therapeutics module writer your own practice exam question assignment: attitudes and perceptions quantitative analysis. Poster: 2016 American Association of Colleges of Pharmacy Annual Meeting. Anaheim, California: July 23, 2016.
33. Shewale A, Stolarz A, **Painter JT**, Rusch N, Fischbach L. Poster: Risk of arm lymphedema with taxane and anthracycline use among patients with breast cancer. Poster: Society for Medical Decision Making 37th Annual North American Meeting. Saint Louis, Missouri: October 20, 2015
34. Hammond DA, Renna CE, **Painter JT**, Wilson AS, Jones KM. Implementation and Outcomes from an Interprofessional Simulated Patient Care Experience on End-of-Life Care and Attitudes toward Death. Poster: American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. San Francisco, California: October 19, 2015
35. **Painter JT**, Martin BC, Li C, Bodhani A, Pyne JM. Poster: Decision Analysis Model for Genetic Testing Prior To Antidepressant Treatment. 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Boston, Massachusetts: August 23, 2015. *Pharmacoepidemiology and Drug Safety*. 24(S1): 192-193 [344].
36. **Painter JT**, Castleberry AN. Student perceptions of active learning methods in pharmacy management. Poster: 2015 American Association of Colleges of Pharmacy Annual Meeting. National Harbor, Maryland: July 12, 2015
37. **Painter JT**, Pyne JM, Fortney JC. Podium: Cost-Effectiveness of Telemedicine-Based Collaborative Care for PTSD. Podium: 2015 Academy Health Behavioral Health Interest Group. Minneapolis, Minnesota: June 13, 2015
38. Hammond DA, Smith MN, **Painter JT**, Meena NK, Lusardi K. Comparative incidence of acute kidney injury in critically ill patients. Podium: 44th Critical Care Congress. Phoenix, Arizona: January 17, 2015. *Critical Care Medicine*. 2015; 43(12): 113 [447].
39. Hammond DA, Chiu T, Meena NK, Jagana R, **JT Painter**. Healthcare provider's knowledge of and opinions regarding medication costs in critically ill patients. Podium: 44th Critical Care Congress. Phoenix, Arizona: January 17, 2015. *Critical Care Medicine*. 2015; 43(12): 327 [1302].
40. Brown J, **Painter JT**, Li C, Hutchison L, Martin B. Predictive validity of inappropriate prescribing criteria for adverse drug events, hospitalizations, and emergency department visits: a time-to-event comparison of the Beers and STOPP criteria. Poster: International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress. Amsterdam, Netherlands: November 13, 2014. *Value in Health*. 17(3): A155 [PIH7].
41. **Painter JT**, Castleberry AN. Confidence in pharmacy management skills: the role of gender. Poster: 2014 American Association of Colleges of Pharmacy Annual Meeting. Grapevine, Texas: July 28, 2014.

42. Shewale AR, Shah AB, **Painter JT**. Risk of psychosexual dysfunction between users of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. Poster: 19th Annual International Society for Pharmacoeconomics and Outcomes Research Conference. Montreal, Quebec. June 4, 2014. *Value in Health*. 17(3): A210 [PMH14]
43. Shah AB, Shewale AR, **Painter JT**. Risk of hyponatremia among incident users of antidepressants. Poster: 19th Annual International Society for Pharmacoeconomics and Outcomes Research Conference. Montreal, Quebec. June 4, 2014. *Value in Health*. 17(3): A211 [PMH15].
44. Brown J, **Painter JT**, Li C, Hutchison L, Martin B. Adverse drug events in the elderly occurring in emergency, inpatient, and outpatient departments in an administrative claims database. Poster: 19th Annual International Society for Pharmacoeconomics and Outcomes Research Conference. Montreal, Quebec. June 4, 2014. Podium: 2014 Southern Pharmacy Administration Conference. Oklahoma City, Oklahoma: June 20, 2014.
45. **Painter JT**, Shewale A, Hudson TJ. Characterization of fibromyalgia in veterans. Poster: Academy Health 30th Annual Research Meeting. San Diego, California: June 9, 2014.
46. **Painter JT**, Fortney JC, Pyne JM. Net health benefits of collaborative care for depression in HIV clinics. Poster: 2014 Academy Health Behavioral Health Interest Group. San Diego, California: June 7, 2014.
47. **Painter JT**, Talbert J, Crofford LJ. Geographic variation of chronic opioid use in fibromyalgia. Poster: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Montreal, Quebec: August 25, 2013. *Pharmacoepidemiology and Drug Safety*. 2013; 22: S485-S486 [971].
48. **Painter JT**, Fortney JC, Pyne JM. Cost effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Podium: Academy Health 30th Annual Research Meeting. Baltimore, Maryland: June 22, 2013.
49. **Painter JT**. Effect of prescription monitoring programs on opioid admission rate: an HCUP study. Poster: International Society for Pharmacoeconomics and Outcomes Researchers 16th Annual International Meeting: Baltimore, Maryland: May 21, 2011. *Value in Health*. 2011; 14(3): A197-A198 [PMH65].
50. **Painter JT**, Talbert J. The effect of practitioner type on chronic opioid use in patients with fibromyalgia syndrome. Poster: Academy Health Annual Research Meeting. Boston, Massachusetts: June 27, 2010.
51. **Painter JT**, Talbert J. Chronic opioid use in Kentucky Medicaid patients with fibromyalgia syndrome. Poster: American Society of Health-System Pharmacists 44th Midyear Clinical Meeting. Las Vegas, Nevada: December 6, 2009.
52. **Painter JT**, Talbert J. Medication utilization patterns in Kentucky Medicaid patients with fibromyalgia syndrome: a retrospective cohort study. Poster: Academy Health 26th Annual Research Meeting. Chicago, Illinois: June 28, 2009.
53. **Painter JT**, Blumenschein KB. Consumer willingness to pay for pharmacy services: a review of the literature. Poster: International Society for Pharmacoeconomics and Outcomes Researchers 14th Annual International Meeting: Orlando, Florida: May 16, 2009. *Value in Health*. 13(3): A92-A93 [PHP61].
54. **Painter JT**, Fink III JL. Using bulletin board postings to increase students' awareness of pharmaceutical policy issues. Poster: American Pharmacists Association Annual Meeting. San Antonio, Texas: April 3, 2009. *Journal of the American Pharmacists Association*. 2009 (Mar-Apr); 49:290 [180].
55. **Painter JT**, Talbert J. Risk of stroke associated with antipsychotic use: a retrospective cohort study. Poster: American Society of Health-System Pharmacists 43rd Midyear Clinical Meeting. Orlando, Florida: December 7, 2008.

FUNDING

Current

Behavioral Health QUERI: Advancing 21st Century Mental Health Care for Veterans. VA QUERI, QUE 20-026. Principal Investigator: Sara Landes; Role: **Co-Investigator**. \$5,000,000. 2020-2025.

Comparing Effectiveness PTSD Trial of Sequenced Pharmacotherapy and Psychotherapy in Primary Care. PCORI, PTS-2019-C1-15636. Principal Investigator: John Fortney; Role: Co-Investigator. \$6,824,6666. 2019-2025.

Whole Health Options & pain Education (WHOPE) Study. UH3 AT 009765 NIH. Principal Investigator: Karen Seal; Role: **Site Principal Investigator**. \$1,504,944. 2020-2023.

Center for Mental Healthcare and Outcomes Research. Principal Investigator: Richard Owen; Role: **Co-Investigator**. VA HSR&D, CIN 13-411, \$2,625,000. 2019-2023.

Evaluating Expanded Access to TeleYoga to Reduce Pain in Rural Veterans. Principal Investigator: Nicosia; Role: **Co-Investigator**. VA Office of Rural Health, OMAT 16016. \$344,729. 2021-2022

Implementing Caring Contacts for Suicide Prevention in Non-Mental Health Settings. Principal Investigator: Sara Landes. Role: **Co-Investigator**. \$1,250,000. 2019-2022.

Precision Medicine in Mental Health Care. VA HSR&D Service Directed Research. Principal Investigator: David Oslin; Role: **Co-Investigator**. \$11,000,000. 2017-2022.

Completed

Comparative effectiveness of patient-centered strategies to improve pain management and opioid safety for Veterans. PCORI 1511-33052. Principal Investigator: Erin Krebs; Role: **Co-Investigator**. \$12,499,310. 2016-2021.

National Advanced Care Planning and Advanced Directive Center. Principal Investigator: Kimberly Garner; Role: **Co-Investigator**. VHA ORH 6108-10P3C. 2018-2021.

HIV Translating Initiatives for Depression into Effective Solutions (HITIDES) – Hybrid Type 3 Implementation-Effectiveness Trial: Developmental Formative Evaluation. VA HSR&D, SDR 19-500. Role: **Principal Investigator**. \$150,000. 2020-2021.

Improving Pain-Related Outcomes for Veterans (IMPROVE). VA QUERI Service Directed Project, Principal Investigator: Will Becker; Role: **Site Principal Investigator**. \$4,117,220. 2016-2020.

Risk Stratified Enhancements to Clinical Care: Targeting Care for Patients Identified Through Predictive Modeling as Being at High Risk for Suicide. VA HSR&D Service Directed Research. Principal Investigator: Sara Landes; Role: **Co-Investigator**. \$875,597. 2016-2020.

The Use of Cefepime as a Carbapenem-Sparing Antibiotic in the Treatment of Bacteremia Due to AmpC B-Lactamase-Producing Enterobacteriaceae. UAMS COP Seed Grant. Role: **Principal Investigator**. \$10,500. 2018-2019

Antihypertensive-Associated Risk of Lymphedema in Breast Cancer Patients Treated with Doxorubicin. UAMS COP Seed Grant. Principal Investigator: Amanda Stolarz; Role: **Co-Investigator**. \$11,500. 2018-2019.

Center for Mental Healthcare and Outcomes Research. Principal Investigator: Richard Owen; Role: **Co-Investigator**. VA HSR&D, CIN 13-411, \$2,750,000. 2014-2018.

Opioid Consent Helping Optimize Information for Cancer and Effective (CHOICE) Pain Management Project. VA ORD, Principal Investigator: Karl Lorenz; **Co-Investigator**. \$499,975. 2016-2018.

Examining concomitant psychotropic medication use in opioid using Veterans. MIRECC Locally Initiated Project. Role: **Principal Investigator**. \$12,000. 2017.

Concomitant Vasopressin and Norepinephrine versus Norepinephrine Alone in Critically Ill Adult Patients with Septic Shock. AACP Critical Care PRN Member Research Grant, Principal Investigator: Drayton Hammond; Role: **Co-Investigator**. \$7,500. 2015-2017.

Risk Stratified Enhancements to Clinical Care: Targeting Care for Patients Identified Through Predictive Modeling as Being at High Risk for Suicide. VA HSR&D Planning Grant. Principal Investigator: Sara Landes; Role: **Co-Investigator**. \$342,204. 2016.

Characterization of implementation facilitators and barriers in VA HIV clinics: examination of the inner setting. CeMHOR Locally Initiated Project. Role: **Principal Investigator**. \$17,947. 2016.

Cost effectiveness analysis of a telemedicine-based collaborative care for PTSD. VA South Central Veterans Health Network Pilot Project Grant Program, Role: **Principal Investigator**. \$100,000. 2014-2016.

Evaluation of medication synchronization in Arkansas community pharmacies. National Community Pharmacists Association. Research Contract; Role: **Principal Investigator**. \$15,000. 2014-2015.

Off-label use of anti-psychotics: determinants, costs, and impact on patient safety. Principal Investigator: Teresa J. Hudson; Role: **Co-Investigator**. VA HSR&D, RRP 11-379, \$99,353, 2012-2013.

Center for Mental Healthcare and Outcomes Research. Principal Investigator: Richard Owen; Role: **Co-Investigator**. VA HSR&D, HFP 09-155, \$4,840,000, 2009-2013.

Pending applications

Painter JT. Implementation of collaborative care for depression in VA HIV clinics: Translating Initiatives for Depression into Effective Solutions (HITIDES). Resubmission: December 2018. \$978,861.

SERVICE

Public

Membership Committee

AcademyHealth; Member July 2018-Present

Annual Research Meeting Planning Committee

AcademyHealth; Member July 2018-Present

Behavioral Health Services Research Advisory Committee

AcademyHealth; Member, July 2015-Present; Vice-chair, July 2016-June 2017; Chair July 2017-June 2018

Pain Board

Central Arkansas Veterans Healthcare System; Member, October 2016-Present

University

Intercollegiate Faculty Council

University of Arkansas for Medical Sciences; Member, January 2021

IPE Faculty Development Pillar Team

University of Arkansas for Medical Sciences; Member, January 2021

Educators Academy Advisory Committee

University of Arkansas for Medical Sciences; Member, June 2017-Present; Reviewer, June 2017-Present

College

Promotion and Tenure Committee

University of Arkansas for Medical Sciences; Member, July 2017-Present

Student Research Committee

University of Arkansas for Medical Sciences; Member, July 2017-Present

Educational & Technology Support Advisory Committee

University of Arkansas for Medical Sciences; Member, July 2016-Present

Research Certificate Program Committee

University of Arkansas for Medical Sciences; Member, July 2019-Present

Pharmacy Practice Postgraduate Education Committee

University of Arkansas for Medical Sciences; Member, July 2015-June 2017; Chair, July 2015-June 2016

Pharmacy Practice New Faculty Member Development Committee

University of Arkansas for Medical Sciences; Member, February 2013-July 2013

Division

Pharmaceutical Evaluation and Policy Graduate Student Advisory Committee

University of Arkansas for Medical Sciences; Member, January 2013-Present; Co-chair, July 2015-June 2016

Invited Presentations

1. **Painter JT.** Advance care planning via group visits: Partnering to discern implementation strategies from stakeholder activities. Academy Health 13th Annual Conference on the Science of Dissemination and Implementation. December 15, 2020.
2. **Painter JT.** Approaches to Educational Research: Best Practices to Answer Your Question. University of Arkansas for Medical Sciences Teaching Scholars Program. Little Rock, Arkansas: February 12, 2019.
3. **Painter JT.** Approaches to opioid optimization and pain management: overview of CAVHS options. Little Rock Air Force Base Medical Lunch and Learn. Little Rock AFB, Arkansas. November 6, 2018.
4. **Painter JT.** Test and Item Analysis. University of Arkansas for Medical Sciences, Teaching Certificate Program. Little Rock, Arkansas: July 24, 2017; July 17, 2018.
5. **Painter JT.** The Cost of Drugs. Lifequest of Arkansas. Little Rock, Arkansas. May 16, 2018.
6. **Painter JT.** Determining the Appropriateness of Off-Label Antipsychotic Use for Mental Health Indications. University of Arkansas for Medical Sciences, Department of Psychiatry Grand Rounds. Little Rock, Arkansas: August 1, 2016.
7. **Painter JT.** The Value of Pharmacists: Medication Adherence. Mercer University College of Pharmacy, Center for Clinical Outcomes Research and Education. Atlanta, Georgia: April 13, 2016
8. **Painter JT.** Opioid Abuse and Misuse Epidemic: Examining the Policy Landscape. University of Arkansas for Medical Sciences Pharmacy Update. Little Rock, Arkansas: December 13, 2015.
9. **Painter JT.** Introduction to Cost-Effectiveness Analysis. Veterans Affairs Geriatric Research, Education and Clinical Center. North Little Rock, Arkansas: November 2, 2015.
10. **Painter JT.** Seniors and Drugs of Abuse. Invited presentation: University of Arkansas for Medical Sciences 16th Annual Geriatrics and Long-Term Care Update. Little Rock, Arkansas: September 27, 2015.
11. **Painter JT.** Writing your *curriculum vitae*. Invited presentation: Arkansas Association of Health-System Pharmacists 48th Annual Fall Seminar. Little Rock, Arkansas: October 3, 2014. Invited presentation: Harding University College of Pharmacy. Searcy, Arkansas: October 30, 2014. 47th Annual Fall Seminar. Little Rock, Arkansas: October 4, 2013.

REVIEWER

Meeting abstracts

AcademyHealth. 2017 Annual Research Meeting Behavioral Health Services Research Topic Highlights.
AcademyHealth. 2015-2017 Behavioral Health Services Research Annual Adjunct Meeting.

Chapters

American College of Clinical Pharmacy. 2016-2018 Pharmacotherapy Self-Assessment Program Journal of Pharmacy Practice: Fibromyalgia.

Grants

Department of Veterans Affairs. Scientific Merit Review Board Subcommittee on Health Care and Clinical Management. Standing Member, 2020-2024.
Uniformed Services University. Health Services Research Program. 2018-Present.
Netherlands Organization for Health Research and Development. 2016 Efficiency Research Grants Program.

Journals

Journal of General Internal Medicine
International Journal of Pharmacy Practice
Arthritis Care & Research
Currents in Pharmacy Teaching and Learning
American Journal of Pharmacy Benefits
Journal of the American Pharmacists Association
Pharmacy Practice
Psychiatric Service
Pain Medicine

ORGANIZATIONAL MEMBERSHIPS

International Society for Pharmacoepidemiology
American Society of Health-System Pharmacists
The Phi Kappa Psi Fraternity
AcademyHealth

HONORS, AWARDS, AND LICENSURES

Awarded: Outstanding Author, Journal of the American Pharmacists Association (2020)
Awarded: Best New Investigator, Arkansas College of Clinical Pharmacy (2015)
Licensed: Registered Pharmacist, Arkansas Board of Pharmacy (2014-present)
Licensed: Registered Pharmacist, Kentucky Board of Pharmacy (2009-present)
Commissioned: The Honorable Order of Kentucky Colonels (2012)
Awarded: Oscar C. Dilly Excellence in Pharmacy Administration (2009)
Awarded: 1st Place Poster, Rho Chi Research Day; University of Kentucky (2009)
Inducted: Phi Lambda Sigma Leadership Honor Society (2006)